Martin Babler - 14 Jun 2024 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRLD	Director Stock Option (Right to Buy)	Award	$0	+23,500		$0.000000	23,500	14 Jun 2024	Common Stock	23,500	$3.90	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date.